Cancer Drug

The SEC brought a <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/09/Cancer-drug.pdf">federal complaint</a></strong> demanding an injunction, disgorgement and penalties against Clovis Oncology, its CEO and former CFO for misrepresenting the efficacy of their cancer drug rociletinib.

DENVER — The SEC brought a federal complaint demanding an injunction, disgorgement and penalties against Clovis Oncology, its CEO and former CFO for misrepresenting the efficacy of their cancer drug rociletinib.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.